PAPR Inhibitors May Work Against More Ovarian Cancers

PAPR inhibitors, first used in trials for women with ovarian cancer who had a mutation in the BRCA1 or BRCA2 gene, are now being used in trials for women without these genetic mutations and showing some effect. In a recent trial, olaparib shrunk the tumors in 41 percent of patients with a genetic mutation and 24 percent of those without it.

The abstract of the study can be found here